AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 3 E 3rd Ave, San Mateo,california 94401,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ausperbio.com
- HQ
- San Mateo, California
Ausperbio Questions
Ausperbio's website is http://www.ausperbio.com
Ausperbio's LinkedIn profile is https://www.linkedin.com/company/ausperbio
Ausperbio has
5 employees.
View email and phone details for 5
employees at Ausperbio.
Ausperbio's industry is
Biotechnology Research
Ausperbio's top competitors are
Cellcentric,
Juvenescence®,
杭州浩博医药有限公司 Ausperbio,
Haya Therapeutics,
Repronovo,
Newlimit,
Grin Therapeutics, Inc.,
Syndeio Biosciences,
Stylus Medicine,
Azafaros B.v..
Ausperbio's categories are Biotechnology Research
Ausperbio's founding year is 2019
